The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully understood how liraglutide induces weight loss or to what degree liraglutide acts directly in the brain. Here, we determined that liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus. Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus. GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r(-/-) mice. In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling. Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1R and GIP-R have been identified in brain regions involved in the regulation of appetite, satiety, food/energy intake and energy expenditure, which is consistent with the significant impact on body weight observed with incretin therapy.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have demonstrated that the principal sites of action accessible to these drugs are GLP-1R neurons in circumventricular organs, particularly the AP and ME, and those in immediately adjacent regions—the NTS and arcuate nucleus of the hypothalamus (16, 51, 63‐66).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The individual necessity of distinct GLP-1R neuron populations for the anorectic and weight loss effects of GLP-1RAs has now been claimed by multiple studies using various loss-of-function approaches in rodents (47, 50‐54, 69).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies also indicate that tanycytes, specialized glial cells within the CNS, may facilitate the transportation of peripheral GLP-1RAs, such as semaglutide, into the CNS, bypassing the blood-brain barrier to access appetite-regulating hypothalamic regions such as the arcuate nucleus (60, 61).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [61]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent mechanistic studies, primarily conducted in rodents, have identified a number of sites of direct action putatively mediating the effects of GLP-1-based AOMs on eating and body weight, including the area postrema and nucleus tractus solitarius (47‐49), locus coeruleus (50), hypothalamic arcuate (51, 52) and dorsomedial nuclei (53), and the lateral septal nucleus (54).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 9×
“In 7 of 7 cells (from 5 mice), GLP-1(7-36)amide failed to change the current in the presence of bicuculline (Figure 2, D and F), demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.”
InfluentialDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“Physiologically, GLP-1 released from endocrine cells lining the gut acts peripherally (13, 42).”
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 4×
“Given the well-known role of NTS-produced GLP-1 in appetite regulation, it is tempting to speculate that peripheral administration of GLP-1 or analogs activates NTS GLP-1–positive neurons that in turn reduce appetite (22, 23).”
InfluentialObesity is associated with hypothalamic injury in rodents and humans.
Thaler, J. P., Yi, C.-X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M. O., Zhao, X., Sarruf, D. A., Izgur, V., Maravilla, K. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59660 · Cited by 1,857
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“…analogs, like exenatide and lixisenatide, display a marked reduction of GE, which may contribute to short-term effects on food intake, while liraglutide and exenatide, formulated for slow release, have only a minor effect on GE, which then cannot be the mediator of the body weight effects (16, 17).”
Hypothalamic CART is a new anorectic peptide regulated by leptin
Kristensen, P., Judge, M. E., Thim, L., Ribel, U., Christjansen, K. N., Wulff, B. S., Clausen, J. T., Jensen, P. B., Madsen, O. D., Vrang, N., et al. (1998) · Nature · doi:10.1038/29993 · Cited by 1,282 · cited 1×
“…access to the brain and how they may affect the key neuronal pathways that regulate energy balance, such as the neuropeptide Y/agouti-related peptide (NPY/ AgRP) and proopiomelanocortin/cocaine-and amphetamine-regulated transcript (POMC/CART) neurons located in the arcuate nucleus (ARC) (7–11).”
Self-citationAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Liraglutide dose dependently lowers body weight by reducing energy intake via an overall appetite reduction (31, 32).”
NPY/AgRP Neurons Are Essential for Feeding in Adult Mice but Can Be Ablated in Neonates
Luquet, S., Perez, F. A., Hnasko, T. S., & Palmiter, R. D. (2005) · Science · doi:10.1126/science.1115524 · Cited by 1,125
Research works printed but not linked: 1
- Astrup A, Rossner S, Van Gaal L. Effects of lirag- lutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616. · DOI · Paper page
Cited by
Items 701–800 of 958
Exendin-4 increases the firing activity of hippocampal CA1 neurons through TRPC4/5 channels
Sun, H.-Z., Shen, F.-S., Li, X.-X., Liu, C., Xue, Y., Han, X., Chen, X., & Chen, L. (2023) · Neuroscience Research · doi:10.1016/j.neures.2023.08.001 · Cited by 4
Yoo, S., Yoo, E.-S., Kim, J. I., & Sohn, J. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2185 · Cited by 4
“Importantly, previous studies have shown that both drugs activate arcuate POMC neurons to suppress food intake [6,7,14].”
Wu, X., He, J., Wu, J., Liu, W., Xu, Y., Li, Y., Zhang, J., & Wang, Q. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01541-0 · Cited by 4
“These agents mimic the action of endogenous GLP-1 by enhancing glucose-dependent insulin secretion, inhibiting glucagon release, decelerating gastric emptying, and reducing appetite and food intake [5, 6].”
Otowa‐Suematsu, N., Sakaguchi, K., Nakamura, T., Hara, K., Kishi, M., Hashimoto, N., Yokota, K., Yoshino, H., Kuroki, Y., Nishiumi, T., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0505-2 · Cited by 4
Synaptic Regulation of Metabolism
Xu, J., Bartolome, C. L., & Kong, D. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1286-1_4 · Cited by 4
Extrapolation from Clinical Trial to Practice: Current Pharmacotherapy on Obesity
Gorain, B., Choudhury, H., Sengupta, P., Verma, R. K., & Pandey, M. (2021) · Springer eBooks · doi:10.1007/978-981-33-6408-0_10 · Cited by 4
Are GLP-1R agonists the long-sought-after panacea for obesity?
Dowsett, G. K. C., & Yeo, G. S. H. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.06.008 · Cited by 6
A better understanding of the science and reality of obesity is urgently needed
Petre, T., Bauman, A. E., Sumithran, P., Sacks, G., Lobstein, T., le Roux, C. W., Mullen, C., & Oldfield, B. J. (2022) · Public Health Research & Practice · doi:10.17061/phrp3232220 · Cited by 4
Campos, C. (2018) · PubMed · Cited by 4
Singh, I., Wang, L., Xia, B., Liu, J., Tahiri, A., Ouaamari, A. E., Wheeler, M. B., & Pang, Z. P. (2022) · Research Square · doi:10.21203/rs.3.rs-1971723/v1 · Cited by 4
Cassano, D., Aguggia, J. P., Giovanini, L., Heredia, F., Francesco, P. N. D., Andreoli, M. F., Schöth, H. B., Habib, A. M., Fernández, G., & Perelló, M. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112627 · Cited by 3
Crispino, S. P., Nusca, A., Ferro, A., Cricco, R., Ciancio, M., Segreti, A., Cavallari, I., Sabatino, M., Potena, L., Ussia, G. P., et al. (2025) · Biomolecules · doi:10.3390/biom15111574 · Cited by 6
“Key aspects of this mechanism are related to GLP-1RAs and GLP-1R interaction in the hypothalamus arcuate nucleus and hindbrain [25].”
Lateral Septum as a Key Integrative Regulator of Feeding: Role of the GLP ‐1/ GLP ‐ 1R System
Dib, T., Covarrubias, M. J., Escobar, A. P., Renard, G. M., Bravo, J. A., & Sotomayor‐Zárate, R. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70301 · Cited by 3
“It has been proposed that the entry of liraglutide into hypothalamic regions, particularly the ARC, is GLP-1R–dependent (Secher et al. 2014).”
Phan, C., & Wagner, E. J. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.11.038 · Cited by 4
Metabolic beneficial effects of targeting a long non-coding RNA, lnc-megacluster, in obesity
Abdollahi, M., Malek, V., Tanwar, V. S., Kato, M. V., Lanting, L. L., Rezaei, A., Zhang, L., Yang, L., Pillai, R. K., Kebrom, L., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102792 · Cited by 3
Li, H.-Y., Lip, G. Y. H., Chan, T.-K., Yiu, K. H., Tse, H., Martin, C. A., & Chan, Y.-H. W. (2026) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-026-02297-8 · Cited by 6
“Glucagon-like peptide-1 receptor agonists (GLP-1 RA), first used to treat type 2 dia - betes, contribute to weight loss [5 ] through suppressing sig - nals from neurons promoting hunger and enhance signals associated with fullness [6, 7].”
GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease
Gandhi, A., Phyu, E. M., Koom‐Dadzie, K., Dickson, K. B., & Halm, J. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062853 · Cited by 6
“Within the arcuate nucleus, liraglutide activates anorexigenic POMC/CART neurons and suppresses orexigenic NPY/AgRP signaling, providing a neural basis for its weight-loss efficacy [86].”
Ono, Y. O. I., Shinohara, K., Nakashima, H., Miyamoto, R., Hara, A., Ikeda, S., Matsumoto, S., Yoshida, D., Nakashima, R., Matsushima, S., et al. (2026) · Hypertension Research · doi:10.1038/s41440-026-02632-6 · Cited by 3
“In the hypothalamic arcuate nucleus (ARC), anorexigenic proopiomelanocortin (POMC) neurons express GLP-1 receptors, and activation of these neurons has been shown to suppress appetite [14 – 16].”
Generation of human appetite-regulating neurons and tanycytes from pluripotent stem cells
Abay-Nørgaard, Z., Mueller, A. K., Hänninen, E., Belmont-Rausch, D. M., Piilgaard, L., Trujillo, L. S., Fedrizzi, L., Christensen, J. B., Salvador, A., Schörling, A. L., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.05.005 · Cited by 7
Simancas‐Racines, D., Campuzano-Donoso, M., Rossetti, G., Cobellis, L., Pilone, V., Fascì-Spurio, F., Gavilanes, D. J., Soria, C., Reytor-González, C., & Schiavo, L. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100290 · Cited by 3
“…reductions in food volume and dietary variety may decrease overall exposure to micro-nutrients obtained from food (Fe, B 12 , Vitamin D, Zn, Ca), providing a physiological context for the potential micronutrient vulnerabilities explored in subsequent sections [14,25,57,61,62,64,68,69,76,82].”
Baumer-Harrison, C., Graham, M., Jonghe, B. C. D., & Hayes, M. R. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.015 · Cited by 8
Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
Wibawa, I. D. N., Mariadi, I. K., Somayana, G., Kumbara, C. I. Y. K., & Sindhughosa, D. A. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i5.549 · Cited by 4
Oral semaglutide effectiveness and safety in real world practice; The REVOLUTION study
Alsheikh, A., Alshehri, A., ALZAHRANI, S. H., Jammah, A. A., Alqahtani, F., Alotaibi, M. S., Aldahash, R., Alhozali, A. M., Alsabaan, F., Almehthel, M. S., et al. (2024) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2024.100209 · Cited by 4
Review on the role of hypothalamic astrocytes in the neuroendocrine control of metabolism
Farhadi, Z., Khaksari, M., Alivirdiloo, V., Mehrjerdi, F. Z., Alborzi, N., Baktash, K. B., & Rezvani, M. E. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01465-9 · Cited by 4
“Furthermore, GLP-1 is produced by pro - glucagon-expressing neurons in the nucleus of the solitary tracts (NTS) nuclei of the brain and is projected to other areas of the brain, including the hypothalamus [53 ].”
Xu, Z., Wen, S., Dong, M., & Zhou, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16146 · Cited by 4
“13 Other recent studies have shown that GLP-1R is expressed in NPY neurons and the innervating axons.”
Erdogan, C. S., Yavuz, Y., Özgün, H. B., Bilgin, V. A., Ağuş, S., Kalkan, U. F., & Yılmaz, B. (2025) · Acta Physiologica · doi:10.1111/apha.70020 · Cited by 3
Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone
Ferrara, F., Bazzani, D., Crivelli, B., Danieli, E., Gazzola, P., Guarnieri, G., Handschin, G., Lauria, C., Marchetti, C., Sbraga, E., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04319-0 · Cited by 4
“These agents delay gastric emptying, enhance satiety, and reduce caloric intake by acting on GLP-1 receptors located in the arcuate nucleus of the hypothalamus (Ard et al. 2021; Secher et al. 2014).”
Shetty, S., Karunakara, M. B., Kristipati, R. R., Kalthur, G., & Kumari, S. (2025) · F1000Research · doi:10.12688/f1000research.167998.1 · Cited by 2
Case Report: Bilateral Ciliary Body Detachment in a Patient Taking Oral Diet Pills
Li, Y., Yuan, T., Gao, X., & Yu, F. (2021) · Optometry and Vision Science · doi:10.1097/opx.0000000000001743 · Cited by 3
Honda, K., Yasuhara, A., Saneyasu, T., & Kamisoyama, H. (2021) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.67.217 · Cited by 3
A contemporary view on obesity treatment in adults
Velychko, V. I., Mankovsky, B., Татарчук, Т. Ф., Lahoda, D. O., Todurov, I. M., & Ліщишина, О. М. (2021) · Reproductive Endocrinology · doi:10.18370/2309-4117.2021.61.45-50 · Cited by 6
Growth hormone treatment does not augment the anti‐diabetic effects of liraglutide in UCD‐T2DM rats
Swarbrick, M. M., Cox, C. L., Graham, J. L., Knudsen, L. B., Stanhope, K. L., Raun, K., & Havel, P. J. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.392 · Cited by 2
Self-citationThorens, B., & Hodson, D. J. (2024) · Diabetes · doi:10.2337/dbi24-0025 · Cited by 4
Neuroprotective Activity of GLP-1 Analogues: General Understanding of Implementation Mechanisms
Golovina, E. L., Ваизова, О. Е., & Samojlova, J. G. (2024) · Personalized Psychiatry and Neurology · doi:10.52667/2712-9179-2024-4-2-11 · Cited by 4
Medial hypothalamic MC3R signalling regulates energy rheostasis in adult mice
Possa‐Paranhos, I. C., Butts, J., Pyszka, E., Nelson, C., Congdon, S., Cho, D., & Sweeney, P. (2024) · The Journal of Physiology · doi:10.1113/jp286699 · Cited by 6
“…involved in energy homeostasis, such as the leptin receptor (Balthasar et al., 2004; Cowley et al., 2001; Xu et al., 2018) and GLP1R (Fortin et al., 2020; Gabery et al., 2020; He et al., 2019; Kim et al., 2024; Secher et al., 2014), which mediate their effects by acting on multiple neural pathways.”
Efficacy and Safety of Oral Semaglutide in Managing Type 2 Diabetes in India: A Real-World Study
Ray, S., Ray, A., Goutam, S., & Mitra, A. (2024) · Clinical Diabetology · doi:10.5603/cd.102374 · Cited by 5
Treatments for obesity in the context of nonalcoholic steatohepatitis and mental health
Sharma, A., Albhaisi, S. A. M., & Sanyal, A. J. (2022) · Clinical Liver Disease · doi:10.1002/cld.1219 · Cited by 3
Jensen, C. B., Secher, A., Hecksher‐Sørensen, J., Conradsen, K., & Larsen, R. (2015) · Lecture notes in computer science · doi:10.1007/978-3-319-19665-7_38 · Cited by 3
“These areas have previously been identified as being part of the complex system that regulates food intake [13].”
BackgroundSelf-citationDouton, J. E., Acharya, N., Stoltzfus, B., Sun, D., Grigson, P. S., & Nyland, J. E. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.15.460527 · Cited by 3
“fluorescently labeled liraglutide (120 nmol/kg) in the hypothalamus four hours after a single iv injection.(31) Even so, the timing remains unclear regarding the interaction of liraglutide with GLP-1Rs in the brain, particularly in nuclei associated with reward such as the nucleus accumbens and the ventral tegmental a…”
BackgroundProfiling human hypothalamic neurons reveals a candidate combination drug therapy for weight lossPreprint
Chen, H. C., Yang, A., Mazzaferro, S., Mali, I. D., Cahn, O., Kentistou, K. A., Rowley, C., Stewart, N. M., Seah, J. W. E., Pisupati, V., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.18.549357 · Cited by 4
“Although the precise human cellular targets and action of GLP1R agonist remain to be fully elucidated, Liraglutide binds to and activates mouse POMC neurons (Secher et al. 2014).”
BackgroundJovanovic, V. M., Narisu, N., Bonnycastle, L. L., Tharakan, R., Mesch, K. T., Glover, H. J., Yan, T., Sinha, N., Sen, C., Castellano, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.27.601062 · Cited by 3
“In par6cular, GLP1R expressed in POMC neurons of the ARC has been implicated as a mediator of weight loss via effects associated with an6diabe6c drugs ac6ng as incre6n mime6cs 55 .”
BackgroundLu, X., Harada, N., Yasuda, T., Ikeguchi, E., Kobayashi, D., Denda, M., Seno, Y., Yamane, S., Yabe, D., Otaka, A., et al. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0026 · Cited by 2
Fármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Salvador, J. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107035 · Cited by 13
Wang, Y., Qi, F., Li, M., Xu, Y., Li, D., & Cai, P. (2025) · BioScience Trends · doi:10.5582/bst.2025.01087 · Cited by 6
The antidipsogenic action of nesfatin-1 requires activation of a GLP-1 receptor
Bocke, C. R., Yosten, G. L. C., & Samson, W. K. (2025) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00087.2025 · Cited by 2
Szostak, B., Kułaga, M., Kasprzak, A., Grzybek, M., Mazur-Lesińska, D., Wielgosz-Biała, S., Tyszkiewicz, K., Łozowski, B., Kasprzak, M., & Wilczyńska, B. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.361 · Cited by 3
Lin, J., Green, V., Sohal, A., & Roytman, M. M. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002234 · Cited by 3
Zimmermann, T., Bleymehl, K., Haebel, P., Perens, J., Roostalu, U., Hecksher‐Sørensen, J., Doerr, J., Jarosch, S., Lam, D. D., Klein, H., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102326 · Cited by 5
“Liraglutide, as well as semaglutide, exhibit limited deep brain access following peripheral administration and activate neurons in the hypothalamus and the hindbrain that are involved in food intake control [23,24].”
InfluentialSelf-citationWang, N., Guo, H., Song, L., Wang, J., Hu, S., Wang, M., Zhang, D., Jing, Y., Zhang, Y., Wang, M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70571 · Cited by 5
“…anorexigenic pathways during treatment, but withdrawal triggers rebound of orexigenic neuropeptides (AgRP, NPY) and attenuated leptin signalling, 33 a pattern consistent with appetite reactivation playing a central role in WR. Semaglutide enhanced colonic barrier integrity in obese rats via…”
An obligatory role for AgRP neurons in maintaining body temperature during time-restricted feeding
Su, C., Cai, J., Xu, Y., Arenkiel, B. R., & Tong, Q. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156595 · Cited by 2
Zhu, W., Libert, C., & Vanderhaeghen, T. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00416-6 · Cited by 2
“POMC neurons express GLP-1Rs, and liraglutide is able to directly activate these neurons, in which transient receptor potential channel 5 (TrpC5) channels are activated (Secher et al, 2014; He et al, 2019).”
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
Dahshan, A., Khalil, M. I. M., El-Jaafary, S. I., & Yamani, A. (2026) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2026.100461 · Cited by 2
“For liraglutide, brain-region binding/uptake studies show engagement in hypothalamic circuits and GLP-1R-dependent uptake patterns [36].”
Bashaw, A. G., Roman-Ortiz, C., Gao, S. X., Schier, L. A., Borner, T., & Kanoski, S. E. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.006 · Cited by 5
Females Are Completely Resistant to Semaglutide-Induced Muscle Loss in ob / ob Mice
Rout, S., Karasawa, T., Watanabe, S., Chaix, A., Drummond, M. J., Funai, K., & Choi, R. H. (2026) · Diabetes · doi:10.2337/db26-0229 · Cited by 2
“In addition to appetite suppression, GLP-1RAs have effects on systemic metabolic and peripheral tissues, including skeletal muscle, adipose tissue, and liver, although the tissue-specific adaptations remain incompletely understood (9–11).”
AgRP neurons are required for the weight-lowering effects of GLP-1 receptor agonists in female mice
d’Ávila, M., Cavalcanti‐de‐Albuquerque, J. P., Collado‐Perez, R., Liu, Z.-W., Hunter, J., White, A. E., Schlessinger, J., D’Agostino, G., & Horváth, T. L. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2614476123 · Cited by 5
Serendipity and spontaneity – Critical components in 40 years of academia
Langhans, W. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.02.011 · Cited by 3
Subcutaneous infusion of neurosecretory protein GL promotes fat accumulation in mice
Narimatsu, Y., Fukumura, K., Ukena, K., Mimura, A., Furumitsu, M., & Ukena, K. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e07502 · Cited by 3
GLP-1 enhances hyperpolarization-activated currents of mouse cerebellar Purkinje cell in vitro
Liu, Y., Cao, L.-X., Wang, W., Piao, Y.-R., Wang, J.-Y., Chu, C., Bing, Y.-H., & Qiu, D. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1126447 · Cited by 3
Impacts of different pancreatic resection ranges on endocrine function in Suncus murinus
Li, R.-J., Yang, T., Zeng, Y., Natsuyama, Y., Ren, K., Li, J., Nagakawa, Y., & Yi, S. (2024) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v16.i7.2308 · Cited by 2
“…amphetamine-regulated transcript; the neurons are then depolarized by GLP-1 receptor stimulation and inhibit appetite producing NPY/appetite related peptide neurons, leading to decreased appetite and delayed eating[36,37], which are associated with reduced appetite and delayed initiation of meals.”
Approach to the Treatment of Children and Adolescents with Obesity
Hegedus, E., Vidmar, A. P., Mayer, M., Kohli, R., & Kohli, R. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.06.004 · Cited by 2
Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide
Fareed, A., Ghanem, L., Vaid, R., Iftikhar, Z., Rehman, A. U., Sarwar, A., & Asif, M. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.004 · Cited by 4
Nair, P. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416868121 · Cited by 2
Applebey, S. V., Xiao, A. G., Reiner, B. C., & Hayes, M. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70177 · Cited by 2
“…motivation, such as the nucleus accumbens (NAc), 23 bed nucleus of the stria terminalis (BNST), 24 hypothalamic paraventricular nucleus (PVN), 25 thalamic paraventricular nucleus (PVT), 26 central amygdala (CeA), 27 arcuate nucleus of the hypothalamus (Arc), 28 and the ventral tegmental area (VTA).”
CCK Response Deficiency in Synphilin-1 Transgenic Mice
Smith, W. W., Smith, M., Yang, D., Choi, P. P., Moghadam, A. A., Li, T., & Moran, T. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142314 · Cited by 2
“The site of action for amylin is the area postrema [32,33] while long acting GLP-1 agonists have been proposed to have both vagal and non- vagal direct actions in brain [19, 34].”
BackgroundGLP-1 Receptor Agonists for the Treatment of Diabetes and Obesity
Palani, A., Zhou, Y., Halleck, M. M., & Carrington, P. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.13765-5 · Cited by 2
Henry, B. A. (2016) · Neuroendocrinology · doi:10.1159/000455232 · Cited by 3
Neuroendocrine Control of Energy Stores
Cone, R. D., & Elmquist, J. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00035-6 · Cited by 4
Pharmacotherapy for Weight Loss
Lutz, T. A., & Asarian, L. (2017) · CRC Press eBooks · doi:10.1201/9781315120171-13 · Cited by 3
Yamada, S., & Monai, H. (2023) · Journal of Visualized Experiments · doi:10.3791/65902 · Cited by 2
Mechanisms of action and clinical applications of anti-obesity drugs currently available in Korea
Kim, K. K. (2019) · Journal of Korean Medical Association · doi:10.5124/jkma.2019.62.11.588 · Cited by 2
“리라글루타이드는 궁상 핵을 비롯한 시상하부의 여러 부위로 들어가서 GLP-1R을 통해 체중감량 효과를 나타내는데, 특히 궁상핵의 POMC/ CART 뉴런을 직접 자극하고 GABA 신경 전달을 통해 NPY/AgRP뉴런을 간접적으로 억제하여 체중감소 효과를 유발한다[26].”
InfluentialPharmacological treatment of obesity
Ferreira‐Hermosillo, A., Salame, L., & Abruch, D. C. (2018) · PubMed · Cited by 10
Medikamentöse Adipositastherapie – Chancen und Perspektiven
Lautenbach, A., Aberle, J., Meyhöfer, S. M., & Meyhöfer, S. (2021) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-1491-5805 · Cited by 3
“[16] Secher A, Jelsing J, Baquero AF et al.”
BackgroundLecube, A., & López‐Cano, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.66204-9 · Cited by 2
Le, T. D. V., Fathi, P. A., Watters, A. B., Ellis, B. J., Bozadjieva-Kramer, N., Perez, M. B., Sullivan, A. I., Rose, J. P., Baggio, L. L., Koehler, J. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.03.522509 · Cited by 2
GLP-1R agonists activate human hypothalamic neuronsPreprint
Mazzaferro, S., Chen, H. C., Cahn, O., Yang, A., Shepilov, D., Seah, E., Chen, J., Jawahar, B., Alcaino, C., Macarelli, V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.02.587825 · Cited by 4
“Since these agonists increase the electrical activity of rodent POMC neurons (Péterfi et al. 2021; Secher et al. 2014; Dong et al. 2021; Rønnekleiv et al. 2014; He et al. 2019; Singh et al. 2022) and raise their intracellular calcium concentration ([Ca 2+ ] i ), we performed calcium imaging on…”
InfluentialRiera, C. E. (2024) · Diabetes · doi:10.2337/db23-0706 · Cited by 1
“For example, central GLP-1 receptors are required for the anorexigenic and weight loss effects of the GLP-1 receptor agonist liraglutide (25,26).”
BackgroundSrour, L., Ismail, J., Njeim, R., & Eid, A. A. (2024) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-031-62131-4_8 · Cited by 2
The transformative breakthroughs in GLP-1 research recognized by the 2024 Lasker~DeBakey award
Zhou, Y.-F., Li, Q., Wang, L.-G., Lu, Y., Wang, Y., & Yang, J. (2024) · Current Medicine · doi:10.1007/s44194-024-00041-w · Cited by 1
“This mechanism is likely crucial for mediating liraglutide-induced weight loss (Secher et al 2014).”
Mechanisms of glucagon-like-peptide 1 in the brain beyond metabolic effects
Kim, K. S., Park, J. S., & Choi, H. J. (2025) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2448320.160 · Cited by 3
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Mondoh, A., Crotty, M., & le Roux, C. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601060 · Cited by 3
“At the central level, semaglutide stimulates pro-opiomelanocortin/cocaine-and amphetamine-regulated transcript (POMC/CART) neurons while inhibiting orexigenic neuro-peptide Y/agouti-related peptide (NPY/AgRP) neurons within the arcuate nucleus of the hypothalamus [20,22].”
Metabolic and immune dysfunction at the crossroads between type 1 diabetes and neurodegeneration
D’Addio, F., Bucciarelli, L. G., Lunati, M. E., & Fiorina, P. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156471 · Cited by 2
Insights into the mechanisms of body weight control
Pereira, S. (2025) · AJP Advances in Physiology Education · doi:10.1152/advan.00091.2025 · Cited by 1
Lee, J., Park, S., Kim, E., Park, J.-Y., Rhee, M., Hughes, J. W., Ko, S., Kwon, O., & Lee, E. Y. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e44 · Cited by 2
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Contessa, M., Ambrosio, M. R., Fabris, B., & Bernardi, S. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjag003 · Cited by 1
Salama, M., Hassan, D., Vairo, F. P. E., Lteif, A. N., Hentz, R., Olson, O., Pittock, S. T., Nofal, A. A., Creo, A. L., & Kumar, S. (2026) · Pediatric Obesity · doi:10.1111/ijpo.70091 · Cited by 3
“Evidence suggests that, following administration of liraglutide, it is internalised by POMC, cocaine-and amphetamine-regulated transcript (CART) neurons in mice, and may reach the paraventricular nucleus (PVN) of the hypothalamus [32, 33].”
Rakhat, Y., Banno, S., Zhantleu, D., Tsunekawa, S., Yabe, D., Seino, Y., Iwasaki, Y., & Yada, T. (2026) · Nutrients · doi:10.3390/nu18040707 · Cited by 2
“Mechanistically, GLP-1RAs drive the central nervous route via targeting the neurons in the arcuate nucleus of the hypothalamus (ARH) [11,15] and the area postrema (AP) in the brain stem to reduce food intake and weight.”
Sukkar, G., Halabi, M. H., & Faden, Y. H. (2026) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_455_25 · Cited by 1
“[19,24] Within the arcuate nucleus, GLP-1 RAs stimulate pro-opiomelanocortin (POMC) neurons while inhibiting Neuropeptide Y (NPY) neurons; this duality in modulation generates an anorexigenic shift, reducing hunger and subsequent caloric intake.”
Chen, Y., Li, J., Delemotte, L., & Mu, Y. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00224 · Cited by 1
Shevchouk, O. T., Edvardsson, C. E., Ericson, M., Westberg, L., & Jerlhag, E. (2026) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2026.107893 · Cited by 2
Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation
Fallot, L. B., Anderson, C. A., Pinc, J. R., Stevenson, A., Schleck, M. C., Hawryschuk, E., Li, O. Z., Palchak, J. C., Toole, J. R., Kubiak, R. W., II, et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c01289 · Cited by 2
Alanazi, M., Al‐kuraishy, H. M., Mohamed, A. A., Abass, S. A., Shokr, M. M., Alruwaili, M., & Batiha, G. E. (2026) · Current Nutrition Reports · doi:10.1007/s13668-026-00773-1 · Cited by 1
Recent developments in GPCR signalling in appetite regulation
Brittain, H. R., & Gorvin, C. M. (2026) · Bioscience Reports · doi:10.1042/bsr20250120 · Cited by 1
“At the hypothalamus, GLP-1R agonism activates CART and POMC neurons and suppresses NPY/AgRP neurons [63,64].”
Ying, H., Wang, Q., He, Q., Cao, Y., Wei, G., Xiao, Z., & Luo, X. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1834999 · Cited by 2
“This regulates pancreatic β -cell function and insulin secretion via the cAMP/PKA pathway (Salehi et al., 2014; Secher et al., 2014).”
The central amygdala gates exogenous glucagon-like peptide 1 signals
Duran, M., Zeng, N., Cutts, E. J., POLAMARASETTY, A., Rodríguez, M., Habegger, K. M., & Hardaway, J. A. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102403 · Cited by 2
Ruga, S., Matarese, E., Bava, R., Lombardi, C., Dimatteo, T., Miscio, L., Raponi, M., Giordano, A., Sansone, C., Liguori, G., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19081230 · Cited by 1
Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY
Doggrell, S. A. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.995629 · Cited by 1
“Recently, studies in rats, has suggested that liraglutide can cross the blood–brain barrier because of internalization of it receptor and acts at a site distinct from the GLP-1 receptor in the central nervous system to induce weight loss [12].”
BackgroundTherapie der Adipositas und physiologische Regelungsmechanismen
Kern, W. (2017) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/s-0037-1618956 · Cited by 1
Glucagon-Like Peptide 1 and Human Obesity
Anandhakrishnan, A., & Korbonits, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48559-3.00003-8 · Cited by 1
Metadata
- Authors
- Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schäffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N., & Bjerre Knudsen, L.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Gubra (Denmark) (DK)
- Oregon National Primate Research Center (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-09-09
- Volume
- 124
- Issue
- 10
- Pages
- 4473-4488
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4215190
- OpenAlex
- W2014156217
- Cited by
- 961
- References
- 95
- Citations by year
- 2026: 100 · 2025: 126 · 2024: 123 · 2023: 85 · 2022: 77 · 2021: 93 · 2020: 56 · 2019: 63 · 2018: 62 · 2017: 65 · 2016: 52 · 2015: 53 · 2014: 5
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, GLP-1 receptor, arcuate nucleus, weight loss, hypothalamus, proopiomelanocortin neurons, neuropeptide Y, agouti-related protein, GABAergic inhibition, circumventricular organs, GLP-1 analogues, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cocaine- and Amphetamine-Regulated Transcript Protein, Animals, Arcuate Nucleus of Hypothalamus, Body Weight, Disease Models, Animal, Electrophysiology, Hypothalamus, Male, Mice, Transgenic, Nerve Tissue Proteins, Neurons, Paraventricular Hypothalamic Nucleus, Pro-Opiomelanocortin, Vagus Nerve, Weight Loss, Rats, Sprague-Dawley, Receptors, Glucagon, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.